<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010166</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000068452</org_study_id>
    <secondary_id>CCCWFU-57198</secondary_id>
    <secondary_id>NCI-104</secondary_id>
    <nct_id>NCT00010166</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas</brief_title>
  <official_title>Phase II Trial Of Adjuvant 2'2'-Difluoro-2'-Deoxycytidine (Gemcitabine) And External Beam Radiation For The Treatment Of Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gemcitabine may&#xD;
      make tumor cells more sensitive to radiation therapy. Combining chemotherapy with radiation&#xD;
      therapy after surgery may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with radiation&#xD;
      therapy in treating patients who have undergone surgery to remove cancer of the pancreas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the time to disease progression, local control, and survival of patients with&#xD;
           previously resected pancreatic cancer treated with adjuvant gemcitabine and&#xD;
           radiotherapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30-60 minutes on days 1, 4, 8, 11, 15, 18, 22, 25, 29,&#xD;
      and 32 and undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38 in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Beginning at least 4 weeks after chemoradiotherapy, patients without disease progression and&#xD;
      with less than 10% weight loss during study receive additional gemcitabine IV over 30 minutes&#xD;
      on days 1, 8, and 15. Treatment repeats every 28 days for a total of 2 courses.&#xD;
&#xD;
      Patients are followed every 8 weeks for 6 months and then every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 72 patients will be accrued for this study within 2.2 or 3.4&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2000</start_date>
  <completion_date type="Actual">October 3, 2003</completion_date>
  <primary_completion_date type="Actual">October 3, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">26</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Prior gross total resection via a pancreaticoduodenectomy (Whipple resection or&#xD;
                  total pancreatectomy) within the past 2 months&#xD;
&#xD;
          -  No clinical evidence of gross residual disease at time of surgery&#xD;
&#xD;
               -  No focally positive margins (tumor at the margin)&#xD;
&#xD;
          -  No unresected nodal disease or metastatic disease to the liver, peritoneal surfaces,&#xD;
             or elsewhere&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count greater than 1,500/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Able to maintain adequate oral nutrition&#xD;
&#xD;
          -  Documented stable weight (no more than 5 lbs weight loss) for at least 2 weeks prior&#xD;
             to study&#xD;
&#xD;
          -  No other malignancy within the past 2 years except inactive nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix or breast&#xD;
&#xD;
          -  Non-metastatic prostate cancer allowed if more than 2 year survival likely&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study or limit&#xD;
             survival to less than 2 years&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent routine growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for pancreatic cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior abdominal radiotherapy for pancreatic cancer&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur William Blackstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006 Aug 7;95(3):260-5. Epub 2006 Jul 25.</citation>
    <PMID>16868545</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

